VALERIO GRISTINA
@unipa.it
Universita di Palermo
Scopus Publications
- Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review
Francesco Felicetti, Rossella Mazzilli, Stefania Gori, Marco Gallo, Alessio Cortellini, Stella D’Oronzo, Valerio Gristina, Antonella Argentiero, Riccardo Candido, Marzia Del Re, Stefano Fogli, Tindara Franchina, Dario Giuffrida, Giampiero Marino, Matteo Monami, Monica Montagnani, Lelio Morviducci, Annalisa Natalicchio, Alberto Ragni, Valerio Renzelli, Laura Sciacca, Enzo Tuveri, Francesco Giorgino, Matteo Verzé, Maria Chiara Zatelli, Emanuela Arvat, Francesco Perrone, Fabrizio Stracci, Gianluca Aimaretti, Angelo Avogaro, Raffaella Buzzetti, Nicola Silvestris, Antongiulio Faggiano
Journal of Endocrinological Investigation, 2026
Background Cancer survivors have been considered individuals who have completed anti-tumor treatment and are in “remission”. However, the definition is increasingly seen as insufficient due to a significant number of patients living with chronic or stable disease, as a result of advanced therapies, and according to a recent definition, “survivors” are all people living with and beyond cancer. Breast, prostate, lung and colorectal cancers are the most frequent tumors diagnosed in Europe with an increasing population of survivors. The longer life expectancy has made it necessary to assess the health status, comorbidities, and complications in cancer patients, mainly in the age range of 20–50 years. In particular, the long-lasting hormonal therapies in hormone-sensitive tumors and the immunotherapies, that are changing the cancer clinical scenario, have opened a broad landscape of late endocrine/metabolic toxicities. Purpose The aim of the present manuscript is to evaluate the late endocrine-metabolic complications in survivors of young adult or adult-onset cancers in the most prevalent tumors, analyzing risk factors for endocrine/metabolic disease, attempting to provide a indications for long-term surveillance and treatment strategies. Conclusions This paper highlights the importance of recognizing endocrine and metabolic complications, as well as identifying key risk factors that can suggest a more effective surveillance and management. - Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies
Valerio Gristina, Umberto Malapelle, Gennaro Daniele, Giovanni Maria Iannantuono, Tancredi Didier Bazan Russo, Rossana Berardi, Giordano Domenico Beretta, Ettore Domenico Capoluongo, Marcello Ciaccio, Romano Danesi, Marzia Del Re, Matteo Fassan, Giuseppe Giuffrè, Stefania Gori, Lorena Incorvaia, Antonio Marchetti, Nicola Normanno, Carmine Pinto, Daniele Santini, Andrea Sartore Bianchi, Nicola Silvestris, Pierosandro Tagliaferri, Giancarlo Troncone, Massimo Di Maio, Francesco Perrone, Antonio Galvano, Christian Rolfo, Antonio Russo
Journal of Liquid Biopsy, 2026
Liquid biopsy (LB) offers a minimally invasive alternative to tissue biopsy by detecting tumor-derived analytes in biological fluids. Nonetheless, its adoption is limited by variability in methodologies. Therefore, this study used a modified RAND/UCLA approach involving 23 experts of the field, providing two questionnaires that assessed agreement on 22 items. Consensus was reached for all the pre- and post-analytical phase items, agreeing on the pivotal role of plasma cfDNA. Conversely, opinions varied regarding other biomarkers and biological samples. Furthermore, turnaround time and disease setting resulted as two of the most important analytical parameters for choosing testing methodology. Particularly, a complementary tissue-liquid approach with sampling interval ≤2 weeks was preferred. To conclude, a strong consensus on sample handling, biomarker prioritization, and clinical applications is achieved. However, significant heterogeneity remains regarding novel biomarkers, sampling strategies, and costs. Standardization and validation are needed to enhance the clinical adoption of LB. - Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study
Giulia Pasello, Claudia Proto, Carlo Genova, Alberto Pavan, Elisa Roca, Gabriele Minuti, Carmine D’Aniello, Raffaele Giusti, Sabrina Mariotti, Francesco Jacopo Romano, Valentina Polo, Lorenzo Belluomini, Editta Baldini, Francesca Mazzoni, Anna Cecilia Bettini, Valerio Gristina, Alessandro Russo, Francesco Grossi, Francesca Rita Ogliari, Francesco Gelsomino, Rita Chiari, Emilio Bria, Iacopo Fioroni, Diego Cortinovis, Elio Gregory Pizzutilo, Anna Zanetti, Giuseppe Pasqualetti, Barbara Roncari, Lucia Simoni, Annamaria Catino, Stefano Zanini, Vanessa Ruzzarin, Mattia De Nuzzo, Elena Tosoni, Giorgio Madonia, Valentina Marino, Viola Cutifani, Sara Pilotto, Jessica Insolda, Marco Sposito, Ilaria Francesca Furfaro, Alessia Longo, Arianna Fabbri, Davide Mannini, Alice Lunghi, Lorenzo Antonuzzo, Francesca Zepponi, Enrico Caliman, Alice Bardocci, Lucia Bonomi, Salvatore Intagliata, Laura Ghilardi, Silvia Moroni, Monica Gesualdo, Vincenzo Gennusa, Veronica Franchina, Paola Muscolino, Federico Cappuzzo, Vittoria Iorio, Eva Mazzotti, Mirella Moro, Giusy Parisi, Cristiano Serci, Rosa Maria Di Mauro, Marta Brambilla, Alessandra Carbone, Ilaria Vallini, Nicola Fogale, Maria Grazia Viganò, Roberto Viganò, Alessandra Bulotta, Michele Ferrara, Sara Oresti, Giovanna Marrapese, Stefano Stabile, Francesca Martinelli, Francesca Sperandi, Andrea De Giglio, Claudia Fusco, Serena Cosentino, Giulia Marcantognini, Eleonora Valli, Mattia Banfi, Vincenzo Montesarchio, Silvia Bianco, Ivana Caprice, Alessandro Contaldi, Giuseppe Viscardi, Antonietta Guida, Rosaria Laudiero, Manuela Otero, Raffaella Stefania Siesto Andrea Planeta, Giulia Barletta, Linda Zinoli, Maria Caterina Russo, Alessandro Scala, Susanna Yedro, Roberto Ginesi, Teresa Ginesi
Frontiers in Oncology, 2026
Background Following the ADAURA study results, showing that adjuvant osimertinib was associated with significant improvement in disease-free survival among patients with stage IB-IIIA epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung carcinoma (NSCLC), an Early Access Program (EAP) was activated in Italy to provide preapproval access to osimertinib. Methods The ELBA observational retrospective cohort study aims to describe the characteristics, diagnostic workup, mutation testing, and treatment patterns of the patients included in the ADAURA EAP. The retrospective observation period was from the day of the first procedure leading to the pathological diagnosis of NSCLC (index date) to osimertinib initiation and data were obtained from medical records or other original documents available at the sites. Results Overall, 71 patients were evaluable, mainly females (73.2%), with mean (SD) age of 67.5 (8.7) years. Age-adjusted Charlson Comorbidity Index scored 2 or 3 for 74.7% of patients without considering lung cancer. Forty-six (66.7%) out of 69 evaluable patients with available data were discussed at the multi-disciplinary team meeting. The median (25 th -75 th percentiles) time from the initial diagnostic suspicion to the index date was 52.0 (30.0-67.0) days and from index date to EGFR test prescription 20.0 (0.0-42.0) days. Among patients with available data (N = 69), the tests were mostly single-gene polymerase chain reaction mutation-specific test (63.8%) and next-generation sequencing (33.3%). Primary tumor surgery was mostly lobectomy (n/N=63/71, 88.7%). Pathological staging was IB for 21.1% of patients, II for 43.7% and III for 35.2%. Adjuvant chemotherapy prior to osimertinib was administered in 32.4% of patients. Osimertinib was started after a median (25 th -75 th percentiles) time from tumor resection of 2.9 (2.1-4.9) months. Conclusions The ELBA Study showed an evolving landscape in biomarker-driven and molecular targeted therapies in early-stage NSCLC management towards the integration of mutational testing into clinical practice, with a growing focus on an optimal definition of adjuvant treatment. - Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study
Lorena Incorvaia, Mattia Puglisi, Marco Maruzzo, Giulia Mammone, Orazio Caffo, Giuseppe Procopio, Lorenzo Antonuzzo, Mimma Rizzo, Vincenza Conteduca, Carlo Messina, Sarah Scagliarini, Brigida Maiorano, Matteo Santoni, Gaetano Facchini, Helga Lipari, Luigi Formisano, Marco Stellato, Umberto Basso, Sabrina Rossetti, Eleonora Lai, Carlo Carmelo Arcara, Enrico Bronte, Tancredi Didier Bazan Russo, Giovanni Colletta, Valerio Gristina, Francesco Pepe, Umberto Malapelle, Daniele Santini, Ilaria Depetris, Massimo Di Maio, Giuseppe Badalamenti, Sergio Bracarda, Antonio Russo
Oncologist, 2025
Background Evidence on homologous recombination repair (HRR) mutation prevalence in prostate cancer (PC) patients and the diagnostic testing path to guide treatment remains limited outside of clinical trials. The objective of this study was to investigate the DNA source, type of tumor tissue, timing for testing in the patient’s disease course, and rate of conclusive results in a real-world population. Patients and Methods This was an observational, cohort study, involving 20 Italian cancer centers. The study population included consecutive PC patients undergoing germline, tumor, and/or plasma circulating tumor DNA (ctDNA) to profile HRR genes between January 1, 2020 and January 31, 2025. Results Among 1400 PC patients included, 248 (17.7%) showed (likely)pathogenic variants (PVs) in the HRR genes. Most HRR testing was conducted during the metastatic castration-resistant PC (mCRPC)(779, 62.8%). The rate of conclusive results was 89.7% and varied widely according to the type of tumor tissue. The prevalence of HRR alterations was 18.1% in the mCRPC and 13.8% in the hormone-sensitive PC (P = .06). The concordance between tumor testing and ctDNA was 83.9%. Interestingly, 4.6% reported ctDNA testing positive but tumor testing negative, leading to important therapeutic implications. The prevalence of positive ctDNA testing was 47.4% vs 10.5%, for testing within 1 month or over 3 months, respectively, from the initiation of a new line of therapy. Conclusion This large real-world study, through the workflow adopted by clinicians for HRR genomic testing, provides novel insights into the variables influencing the success rate of genomic testing. - Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL
P.M. Medusa, N. Carro, F. Morgillo, G.Di Guida, V. Nardone, M. Gilli, G. Viscardi, C. Borrelli, G. Totaro, R. Costanzo, V. Sforza, A. Manzo, G. Esposito, A. Montanino, A. Servetto, F. Salomone, A. Viggiano, F. Ambrosio, R.Di Liello, T. Fabozzi, S. Feliciano, R. Ronga, L. Notizia, A. Russo, G. Motta, V. Gristina, F. Spinnato, C. Sergi, F. Buzzacchino, A. Ungaro, T.Del Giudice, L. Montella, A.C. Tralongo, Vittorio Simeon, C.M. Della Corte, F. Vitiello
Lung Cancer, 2025
INTRODUCTION: Stage III unresectable non-small cell lung cancer (NSCLC) represents a heterogeneous group, for which consolidation immunotherapy with durvalumab, after chemo-radiotherapy, is currently considered the standard of treatment by all national and international guidelines, based on data from the PACIFIC trial. Regarding adverse reactions, pulmonary toxicities represent the most difficult to diagnose and manage. METHODS: It is planned to include 123 patients at 28 sites in Southern Italy experiencing lung cancer in this observational study. The recruitment phase is scheduled to last 24 months (from October 1, 2024, to October 1, 2026) and the followup phase is scheduled to last 24-36 months after durvalumab discontinuation. Retrospective data collection can be considered from 09/01/2023. The duration of the study will be 60 months. We propose to estimate the incidence and grading of pulmonary toxicity from radiation therapy and immunotherapy, according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and to investigate the correlation of pulmonary toxicity with pulmonary function tests (PFTs), with a particular focus on forced expiratory volume in one second (%FEV1) and forced vital capacity (%FVC) based on spirometry, diffusing capacity of the lung for carbon monoxide (%DLCO), partial pressure of arterial oxygen (PaO2) based on arterial blood gas (ABG) sampling and maximal distance that patients can walk at their own pace in 6 min and minimal oxygen saturation (SpO2) during the 6-minute walking test (6MWT). Pulmonary function tests (basal spirometry, DLCO, 6MWT, ABG) are evaluated at Time 0 (baseline), at Time 1 (post- RT), at Time 2 (after 6 cycles of immunotherapy) and at Time 3 (end of treatment). At data cut-off (31 mar 2025), 45 patients were enrolled and 10 patients were screened failure. Among the 45 patients enrolled, there were 7 cases of pulmonary toxicity (15.5 %). All of the cases showed post-actinic pneumonia (4 cases of grade 2, 2 cases of grade 3 and one case of grade 4 pneumonia). TWITTEABLE ABSTRACT: PRELUDIO trial is a study in stage III NSCLC undergoing consolidation immunotherapy with durvalumab, after chemo-radiotherapy, with the aim to estimate the incidence and grading of pulmonary toxicity according to CTCAE and to investigate the correlation of pulmonary toxicity with pulmonary function tests (PFTs), performed per clinical practice. - Potential Applications of PRP-Enhanced Polybutylene Succinate Graft as Vascular Access for Chemotherapy in Oncological Patients: A Systematic Review
Andrea Gottardo, Giulia Bonventre, Tancredi Didier Bazan Russo, Pietro Zanatta, Giulia Lo Monte, Valerio Gristina, Antonio Galvano, Antonio Russo, Attilio Ignazio Lo Monte
Journal of Functional Biomaterials, 2025
This systematic review aimed to evaluate the potential of combining platelet-rich plasma (PRP) and polybutylene succinate (PBS) for the development of vascular grafts in patients undergoing chemotherapy. Relevant articles published in English or Italian were selected through a comprehensive search of MEDLINE (via PubMed) and the Cochrane Library. A total of ten screened articles and two additional relevant studies were included. The synthesis of results was conducted using digital tools, thoroughly reviewed by the authors. The quality assessment of the included studies revealed a medium-to-high risk of bias, with frequent limitations such as small sample sizes, experimental designs, and overall moderate to low methodological quality. Despite the heterogeneity of the findings, the available evidence suggests that radiocephalic graft placement and the use of PBS as a scaffold material, in combination with the growth factors contained in PRP, may improve clinical outcomes and reduce complications related to arteriovenous graft implantation. While promising, the current literature on this topic remains scarce and fragmented, underscoring the need for additional preclinical and clinical research. The proposed approach appears to hold potential for improving vascular access in oncology, but further in vivo validation is essential. This study received no external funding. Registration: PROSPERO ID CRD42025646724. - Pregnancy and miscarriage before epithelial ovarian cancer (EOC) diagnosis in patients carrying germline BRCA1/BRCA2 pathogenic variants.
Tancredi Didier Bazan Russo, Mattia Puglisi, Elga Adriana Cipolla, Giovanni Colletta, Karen Carobene, Pietro Ferraro, Ugo Randazzo, Nadia Barraco, Silvia Contino, Anna Paola Carreca, Adriana Giusi Lo Bosco, Valerio Gristina, Antonio Galvano, Daniele Fanale, Alessandro Perez, Giuseppe Badalamenti, Viviana Bazan, Ignazio Ugo Carreca, Antonio Russo, Lorena Incorvaia
Journal of Clinical Oncology, 2025
e22516 Background: Several case-control studies have been performed to understand the prognostic impact of pregnancy after breast cancer in patients carrying germline BRCA1/2 (g BRCA1/2 ) pathogenic/likely pathogenic variants (PVs). The median age of onset of epithelial ovarian cancer (EOC) diagnosis is higher than breast cancer. Clinical data on fertility, pregnancy outcomes, and abortion rates before the EOC onset are still missing. Previous research showed that g BRCA PV carriers may have a reduced ovarian reserve, earlier menopause than the general population, and defective homologous recombination repair of DNA double-strand breaks in human trophoblast, potentially leading to spontaneous miscarriage. Methods: This was a real-world, hospital-based cohort study to assess the cumulative incidence of pregnancy and miscarriage in a consecutive series of EOC patients who underwent g BRCA1/2 between May 2015 and December 2024. EOC patients carrying PVs in no- BRCA1/2 genes or tumor BRCA1/2 PVs were excluded from the current analysis. Results: From May 2015 to December 2024, 731 EOC patients were included in the analysis: 138 were carriers of g BRCA1/2 PVs (18.9%): 93 in BRCA1 (67.4%), and 45 in BRCA2 (32.6%). The number of patients with at least 1 pregnancy, abortion included, was 91 in the g BRCA carriers vs 192 in the g BRCA non-carriers. Notably, when the incidence of miscarriage between BRCA carriers and non-carriers was compared, the reduced incidence of spontaneous miscarriage was in the group of patients carrying g BRCA PVs [ BRCA carriers vs non-carriers: 11/92 (12.1%) vs 51/192 (26.6%)]. The total number of full-term pregnancies was 205 for g BRCA carriers vs 192 for non-carrier patients. Also, the median number of full-term pregnancies for single patients was higher in the patients harboring g BRCA PVs vs BRCA wild type (2.25 vs 1.5). The total number of miscarriages was 20 among g BRCA carriers vs 70 among non-carriers, with a lower miscarriage rate for individual patients in the BRCA -mutated patients (1.8 vs 1.3). The genetic characteristics and the EOC clinical behavior between parous and nulliparous women, according to BRCA mutational status, were also collected. Conclusions: Genetic diagnosis of constitutional BRCA1/2 PVs mutation raises concerns about the future fertility of female carriers. Interestingly, our data suggested that pregnancy in EOC women carriers of g BRCA1/2 PVs was associated with a reduced incidence of miscarriage than non-carriers. Prospective validation of these findings is required to improve understanding of fetal and obstetric outcomes and to guide counseling for BRCA carrier patients. - Germline evaluation of mismatch repair (MMR) genes in breast cancer patients missing Lynch syndrome criteria: Clinical behavior, preventive paths and therapeutic implications.
Lorena Incorvaia, Laura Cortesi, Tancredi Didier Bazan Russo, Clarissa Mujacic, Emma Zattarin, Alessandro Perez, Elena Barbieri, maria Concetta Vitale, Isabella Marchi, Valerio Gristina, Lavinia Insalaco, Anna Paola Carreca, Chiara Brando, Nadia Barraco, Antonio Galvano, Daniele Fanale, Giuseppe Badalamenti, Viviana Bazan, Ignazio Ugo Carreca, Antonio Russo
Journal of Clinical Oncology, 2025
e22507 Background: Currently,Breast Cancer (BC) is not considered a mismatch repair (MMR)-deficiency (MMRd)–spectrum tumor. The BC patients carrying constitutional MMR pathogenic variants (PVs) are not eligible for dedicated screening programs and risk-reducing strategies, which are addressed only to the BC individual carriers of specific Homologous Recombination Repair (HRR) variants. The MMRd status, as well as the high levels of microsatellite instability (MSI-H) that occur upon loss of the expression of MMR genes, may have direct therapeutic implications for the patients, who may benefit from the treatment with immune-checkpoint inhibitors (ICIs). Methods: This was an observational, hospital-based, cohort study to investigate the prevalence of germline MMR PVs in BC patients who were appropriate candidates for hereditary breast and/or ovarian cancer (HBOC) predisposition evaluation. BC patients were tested through NGS-based multigene panel testing including MMR-associated genes, according to clinical established criteria. Results: Between January 2016 and December 2024, 6.020 BC patients were referred for genetic counseling and HBOC predisposition evaluation. In the cohort of consecutive 5.595 BC patients tested with multigene panel testing, a subgroup of 26 patients resulted carriers of germline MMR PVs. Interestingly, 6 of 26 MMR-mutated patients (23.1%) had also a personal bilateral BC history. The median age at BC diagnosis was 55 (range 31-82). Mutation prevalence showed that PMS2 was the most mutated MMR gene (10 PVs, 38.5%), followed by MLH1 (6 PVs, 23.1%), EPCAM (5 PVs, 19.2%), MSH2 (3 PVs, 11.5%), and MSH6 (2 PVs, 7.7%). Notably, in the MMR - mutated cohort, 73.1% of BC patients (19/26) reported a family history of HRR-associated tumors (BC, ovarian/prostate and/or pancreatic tumors), predominantly BC (78.9%). Conversely, first or second-degree family members with a colorectal or endometrial cancer diagnosis, that represents the main Lynch Syndrome-associate tumors, were reported only for 3 patients (11.5%). The genetic characteristics and the clinical behavior of BC in MMR-, BRCA - and HRR non- BRCA -carriers were also collected. The variant of uncertain significance (VUS) prevalence was described. Conclusions: Our results suggested that, in women who met hereditary BC testing criteria but missed the established Lynch Syndrome clinical or testing criteria, the use of panel testing including MMR genes could lead to the identification of a subgroup of BC patients who are carriers of MMR constitutional PVs, with potential important preventive and therapeutic implications. - On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study
Valerio Gristina, Viviana Bazan, Nadia Barraco, Simona Taverna, Mauro Manno, Samuele Raccosta, Anna Paola Carreca, Marco Bono, Tancredi Didier Bazan Russo, Francesco Pepe, Pasquale Pisapia, Lorena Incorvaia, Giuseppe Badalamenti, Giancarlo Troncone, Umberto Malapelle, Daniele Santini, Antonio Russo, Antonio Galvano
Molecular Oncology, 2025
Extracellular vesicle (EV) monitoring can complement clinical assessment of cancer response. In this study, patients with advanced non‐small cell lung cancer (NSCLC) undergoing osimertinib, alectinib, pembrolizumab or platinum‐based chemotherapy ± pembrolizumab were enrolled. EVs were characterized using Bradford assay to quantify the circulating cell‐free EV protein content (cfEV), and dynamic light scattering to assess Rayleigh ratio excess at 90°, z‐averaged hydrodynamic diameter and polydispersity index. A total of 135 plasma samples from 27 patients were collected at baseline (T0) and at the first radiological restaging (T1). A ∆cfEV < 20% was associated with improved median progression‐free survival (mPFS) in responders versus non‐responders. Specifically, cfEV responders on pembrolizumab had a significantly better mPFS (25.2 months) compared to those on chemotherapy plus pembrolizumab (6.1 months). EGFR‐positive cfEV responders also experienced longer mPFS compared to cfEV non‐responders (35.1 months, 95% CI: 14.9–35.5 vs. 20.8 months, 95% CI: 11.2–30.4). This study suggested that monitoring circulating EV could provide valuable insights into treatment efficacy in NSCLC, particularly for patients receiving pembrolizumab or osimertinib. - BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study
L. Incorvaia, C. Marchetti, C. Brando, T.D. Bazan Russo, M. Bono, A. Perez, L. Congedo, R. Ergasti, L. Castellana, L. Insalaco, S. Contino, V. Gristina, A. Galvano, D. Fanale, G. Badalamenti, A. Russo, G. Scambia, V. Bazan
ESMO Open, 2025
BACKGROUND: Germline pathogenic variants (gPVs) in the breast cancer susceptibility gene 1/2 (BRCA1/2) genes confer high-penetrance susceptibility to breast cancer (BC) and ovarian cancer (OC). Although most female BRCA carriers develop only a single BRCA-associated tumor in their lifetime, a smaller subpopulation is diagnosed with multiple primary tumors (MPTs). The genetic factors influencing this risk remain unclear. Further, in patients with BRCA-mutated tumors, there appears to be a variability in the effectiveness of olaparib treatment. PATIENTS AND METHODS: This real-world, multicenter, observational study aimed to determine whether the location of BRCA gPVs within functional domains (FDs) is associated with the development of MPTs and the magnitude of olaparib benefit. The study population comprised consecutive patients with OC who underwent hereditary cancer genetic testing between May 2015 and March 2023. MPT history was assessed based on mutated genes (BRCA1 or BRCA2) and the location of the PVs within the FDs. Clinical outcomes of olaparib first-line maintenance therapy were evaluated according to BRCA1/2 FD location. RESULTS: The frequency of MPT history in the overall population was 13.3% (118/882), and 20.4% in the BRCA-mutated subpopulation (68/333; P < 0.001). We observed a significant association between the DNA-binding domain (DBD) FD of BRCA2 and MPT. Specifically, 55.6% of BRCA2-mutated patients with PVs in the DBD had a history of BC as a second tumor. At a median follow-up of 48.5 months (95% confidence interval 10-70 months), the 48-month progression-free survival rates were 100.0% for patients with PVs in DBD, 91.7% for those with PVs in other FDs, and 36.4% for those with PVs in the RAD51-binding domain (RAD51-BD) of BRCA2 (P = 0.01). Results in the BRCA1 cohort were not statistically significant. CONCLUSIONS: The results suggest that the location of PVs within BRCA FDs may influence the onset of multiple tumors and the benefit of olaparib in patients with BRCA-mutated OC. These findings could be relevant for cancer prevention efforts, particularly given the increasing number of cancer survivors. However, further understanding is needed before these results can inform clinical decisions. - Genomics and the early diagnosis of lung cancer
Francesco Pepe, Tancredi Didier Bazan Russo, Valerio Gristina, Andrea Gottardo, Giulia Busuito, Giuliana Iannì, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Viviana Bazan, Antonio Russo, Giancarlo Troncone, Umberto Malapelle
Personalized Medicine, 2025 - Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer
Tancredi Didier Bazan Russo, Francesco Pepe, Valerio Gristina, Andrea Gottardo, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Giulia Busuito, Lorena Incorvaia, Juliette Aimee Guerry, Antonio Galvano, Giuseppe Badalamenti, Viviana Bazan, Giancarlo Troncone, Antonio Russo, Umberto Malapelle
Future Oncology, 2025 - Smaller, cheaper, faster: where next for liquid biopsies?
Valerio Gristina, Francesco Pepe, Francesca Rita Ogliari, Tancredi Didier Bazan Russo, Andrea Gottardo, Gianluca Russo, Lorena Incorvaia, Juliette Aimee Guerry, Pasquale Pisapia, Claudia Scimone, Lucia Palumbo, Antonio Galvano, Giuseppe Badalamenti, Viviana Bazan, Giancarlo Troncone, Antonio Russo, Umberto Malapelle
Expert Review of Molecular Diagnostics, 2025 - Part III – Post-analytical phase
Nicola Fusco, Giancarlo Pruneri, Fabio Pagni, Umberto Malapelle
Pathologica, 2025 - Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients
Valerio Gristina, Tancredi Didier Bazan Russo, Nadia Barraco, Andrea Gottardo, Francesco Pepe, Gianluca Russo, Fabio Fulfaro, Lorena Incorvaia, Giuseppe Badalamenti, Giancarlo Troncone, Umberto Malapelle, Antonio Russo, Viviana Bazan, Antonio Galvano
Scientific Reports, 2024 - The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors
Lorena Incorvaia, Tancredi Didier Bazan Russo, Valerio Gristina, Alessandro Perez, Chiara Brando, Clarissa Mujacic, Emilia Di Giovanni, Marco Bono, Silvia Contino, Carla Ferrante Bannera, Maria Concetta Vitale, Andrea Gottardo, Marta Peri, Antonio Galvano, Daniele Fanale, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan
Npj Precision Oncology, 2024 - Scientific Communication and oncology – “The bridge between knowledge and patients”
Antonio Galvano, Andrea Gottardo, Valerio Gristina, Daniele Fanale, Lidia Rita Corsini, Carlo Pavone, Tancredi Didier Bazan Russo, Emilia Di Giovanni, Giuliana Iannì, Ugo Randazzo, Federica Iacono, Alessandro Perez, Chiara Brando, Marco Bono, Viviana Bazan, Lorena Incorvaia, Giuseppe Badalamenti, Saverio Cinieri, Mauro Boldrini, Rossana Berardi, Antonio Russo
Critical Reviews in Oncology Hematology, 2024 - Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
Tancredi Didier Bazan Russo, Clarissa Mujacic, Emilia Di Giovanni, Maria Concetta Vitale, Carla Ferrante Bannera, Ugo Randazzo, Silvia Contino, Marco Bono, Valerio Gristina, Antonio Galvano, Alessandro Perez, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia
Cancer Gene Therapy, 2024 - Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer
Andrea Gottardo, Tancredi Didier Bazan Russo, Alessandro Perez, Marco Bono, Emilia Di Giovanni, Enrico Di Marco, Rita Siino, Carla Ferrante Bannera, Clarissa Mujacic, Maria Concetta Vitale, Silvia Contino, Giuliana Iannì, Giulia Busuito, Federica Iacono, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Antonio Russo, Viviana Bazan, Valerio Gristina
Cytopathology, 2024 - Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature
Andrea Gottardo, Gabriele Tulone, Nicola Pavan, Fabio Fulfaro, Valerio Gristina, Tancredi Didier Bazan Russo, Ornella Prestifilippo, Francesco Claps, Lorena Incorvaia, Antonio Galvano, Antonio Russo, Alchiede Simonato
International Journal of Molecular Sciences, 2024 - Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives
Anna Paola Carreca, Rosaria Tinnirello, Vitale Miceli, Antonio Galvano, Valerio Gristina, Lorena Incorvaia, Mariangela Pampalone, Simona Taverna, Gioacchin Iannolo
Cancers, 2024 - Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family”
Andrea Gottardo, Valerio Gristina, Alessandro Perez, Emilia Di Giovanni, Silvia Contino, Nadia Barraco, Marco Bono, Giuliana Iannì, Ugo Randazzo, Tancredi Didier Bazan Russo, Federica Iacono, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Russo, Antonio Galvano, Viviana Bazan
Journal of Liquid Biopsy, 2024 - Editorial: Real-world data and real-world evidence in lung cancer
Valerio Gristina, Chukwuka Eze
Frontiers in Oncology, 2024 - Dissecting the nuances of cancer epigenomics in liquid biopsy
Valerio Gristina, Umberto Malapelle
Epigenomics, 2024 - Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer
Valerio Gristina, Francesco Pepe, Carlo Genova, Tancredi Didier Bazan Russo, Andrea Gottardo, Gianluca Russo, Lorena Incorvaia, Antonio Galvano, Giuseppe Badalamenti, Viviana Bazan, Giancarlo Troncone, Antonio Russo, Umberto Malapelle
Expert Review of Molecular Diagnostics, 2024 - Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer
Valerio Gristina, Gianluca Russo, Tancredi Didier Bazan Russo, Giulia Busuito, Giuliana Iannì, Pasquale Pisapia, Claudia Scimone, Lucia Palumbo, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Viviana Bazan, Antonio Russo, Giancarlo Troncone, Umberto Malapelle, Francesco Pepe
Expert Review of Respiratory Medicine, 2024 - Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)
L. Incorvaia, G. Badalamenti, G. Novo, S. Gori, L. Cortesi, C. Brando, S. Cinieri, G. Curigliano, G.R. Ricciardi, A. Toss, R. Chiari, R. Berardi, Z. Ballatore, M. Bono, T.D. Bazan Russo, V. Gristina, A. Galvano, G. Damerino, L. Blasi, V. Bazan, A. Russo
ESMO Open, 2024 - KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study
Lorena Incorvaia, Dario De Biase, Margherita Nannini, Elena Fumagalli, Bruno Vincenzi, Ida De Luca, Chiara Brando, Alessandro Perez, Maria A Pantaleo, Silvia Gasperoni, Lorenzo D’Ambrosio, Giovanni Grignani, Thais Maloberti, Erika Pedone, Tancredi Didier Bazan Russo, Alessandro Mazzocca, Laura Algeri, Alessandra Dimino, Nadia Barraco, Roberta Serino, Valerio Gristina, Antonio Galvano, Viviana Bazan, Antonio Russo, Giuseppe Badalamenti
Oncologist, 2024 - Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy
Vito Longo, Carminia Maria Della Corte, Alessandro Russo, Francesca Spinnato, Francesca Ambrosio, Riccardo Ronga, Antonella Marchese, Teresa Del Giudice, Concetta Sergi, Francesca Casaluce, Marina Gilli, Michele Montrone, Valerio Gristina, Vincenzo Sforza, Maria Lucia Reale, Raimondo Di Liello, Alberto Servetto, Helga Lipari, Claudio Longhitano, Laura Vizzini, Anna Manzo, Antonella Cristofano, Loretta Paolelli, Annalisa Nardone, Simona De Summa, Antonella Perrone, Carmela Bisceglia, Caterina Derosa, Valerio Nardone, Giuseppe Viscardi, Domenico Galetta, Fabiana Vitiello
Frontiers in Immunology, 2024 - Network approach in liquidomics landscape
Daniele Santini, Andrea Botticelli, Antonio Galvano, Michele Iuliani, Lorena Incorvaia, Valerio Gristina, Chiara Taffon, Simone Foderaro, Elisa Paccagnella, Sonia Simonetti, Federico Fazio, Simone Scagnoli, Giulia Pomati, Francesco Pantano, Giuseppe Perrone, Elena De Falco, Antonio Russo, Gian Paolo Spinelli
Journal of Experimental and Clinical Cancer Research, 2023 - Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, Chiara Brando, Valerio Gristina, Daniela Cancelliere, Alessia Pivetti, Silvia Contino, Emilia Di Giovanni, Nadia Barraco, Marco Bono, Ambra Giurintano, Tancredi Didier Bazan Russo, Andrea Gottardo, Sofia Cutaia, Erika Pedone, Marta Peri, Lidia Rita Corsini, Daniele Fanale, Antonio Galvano, Giovanni Scambia, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan
Cancer Treatment Reviews, 2023 - Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible
Valerio Gristina, Maria La Mantia, Marta Peri, Federica Iacono, Nadia Barraco, Alessandro Perez, Giuseppe Viscardi, Sofia Cutaia, Tancredi Didier Bazan Russo, Zubair Anwar, Lorena Incorvaia, Fabio Fulfaro, Salvatore Vieni, Gianni Pantuso, Giuseppa Graceffa, Antonio Russo, Antonio Galvano, Viviana Bazan
Critical Reviews in Oncology Hematology, 2023 - The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors
Antonio Galvano, Valerio Gristina, Dalila Scaturro, Tancredi Didier Bazan Russo, Sofia Tomasello, Fabio Vitagliani, Federica Carità, Maria La Mantia, Fabio Fulfaro, Viviana Bazan, Giulia Letizia Mauro, Antonio Russo
Frontiers in Endocrinology, 2023 - The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?
Valerio Gristina, Pasquale Pisapia, Nadia Barraco, Francesco Pepe, Federica Iacono, Maria La Mantia, Marta Peri, Antonio Galvano, Lorena Incorvaia, Giuseppe Badalamenti, Viviana Bazan, Giancarlo Troncone, Antonio Russo, Umberto Malapelle
Expert Review of Molecular Diagnostics, 2023 - Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
Davide Norata, Marta Peri, Giuseppe Roberto Giammalva, Antonino Lupica, Federica Paolini, Lorena Incorvaia, Giuseppe Badalamenti, Valerio Gristina, Antonio Galvano, Antonio Russo, Domenico Gerardo Iacopino, Mauro Silvestrini, Viviana Bazan, Filippo Brighina, Vincenzo Di Stefano
Diagnostics, 2023 - Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
Lorena Incorvaia, Gaetana Rinaldi, Giuseppe Badalamenti, Alessandra Cucinella, Chiara Brando, Giorgio Madonia, Alessia Fiorino, Angela Pipitone, Alessandro Perez, Federica Li Pomi, Antonio Galvano, Valerio Gristina, Nadia Barraco, Marco Bono, Tancredi Didier Bazan Russo, Francesca Toia, Adriana Cordova, Daniele Fanale, Antonio Russo, Viviana Bazan
Therapeutic Advances in Medical Oncology, 2023 - Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors
Alessandra Dimino, Chiara Brando, Laura Algeri, Valerio Gristina, Erika Pedone, Marta Peri, Alessandro Perez, Ida De Luca, Roberta Sciacchitano, Luigi Magrin, Tancredi Didier Bazan Russo, Marco Bono, Nadia Barraco, Silvia Contino, Maria La Mantia, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia
Cancers, 2023 - Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
Lorena Incorvaia, Alessandra Dimino, Laura Algeri, Chiara Brando, Luigi Magrin, Ida De Luca, Erika Pedone, Alessandro Perez, Roberta Sciacchitano, Annalisa Bonasera, Tancredi Didier Bazan Russo, Federica Li Pomi, Marta Peri, Valerio Gristina, Antonio Galvano, Dario Giuffrida, Ivan Fazio, Francesca Toia, Adriana Cordova, Ada Maria Florena, Antonio Giordano, Viviana Bazan, Antonio Russo, Giuseppe Badalamenti
Frontiers in Oncology, 2023 - Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
Valerio Gristina, Nadia Barraco, Maria La Mantia, Luisa Castellana, Lavinia Insalaco, Marco Bono, Alessandro Perez, Delia Sardo, Sara Inguglia, Federica Iacono, Sofia Cutaia, Tancredi Didier Bazan Russo, Edoardo Francini, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Russo, Antonio Galvano, Viviana Bazan
Cancers, 2022 - Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
Giuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, Valerio Gristina, Elio Gregory Pizzutilo, Maria Anna Canciello, Paola Maria Medusa, Fabio Salomone, Gaetano Di Guida, Mariano Mollica, Luigi Aronne, Roberto Scaramuzzi, Filomena Napolitano, Ciro Battiloro, Francesca Caputo, Marina Gilli, Giuseppe Totaro, Carlo Curcio, Danilo Rocco, Vincenzo Montesarchio
Cancers, 2022 - Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code
Giuseppe Cammarata, Nadia Barraco, Ilaria Giusti, Valerio Gristina, Vincenza Dolo, Simona Taverna
Cancers, 2022 - TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: An international performance evaluation study
U. Malapelle, F. Pepe, P. Pisapia, Roberta Sgariglia, Mariantonia Nacchio, M. Barberis, Michel Bilh, L. Bubendorf, R. Büttner, D. Cabibi, M. Castiglia, C. D. de Andrea, D. de Biase, C. Dumur, G. Fontanini, J. Freire, V. Gristina, P. Hofman, M. Ilié, M. Lozano, S. Merkelbach-Bruse, R. Pappesch, Natalie Pelusi, Gianluca Roma, A. Russo, S. Savic, J. Siemanowski, G. Tallini, V. Tischler, S. Vander Borght, B. Weynand, Tom Xu, G. Troncone
Journal of Clinical Pathology, 2022 - Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies
A. Russo, L. Incorvaia, E. Capoluongo, P. Tagliaferri, S. Gori, L. Cortesi, M. Genuardi, D. Turchetti, U. De Giorgi, M. Di Maio, M. Barberis, M. Dessena, M. Del Re, A. Lapini, C. Luchini, B.A. Jereczek-Fossa, A. Sapino, S. Cinieri, Giordano Beretta, Maria Angela Bella, Sergio Bracarda, Nicoletta Colombo, Vincenza Conteduca, Lucia Del Mastro, Antonio Galvano, Valerio Gristina, Valentina Guarneri, Nicla La Verde, Domenica Lorusso, Paolo Marchetti, Nicola Normanno, Laura Ottini, Matilde Pensabene, Sandro Pignata, Giuseppe Procopio, Enrico Ricevuto, Nicola Silvestris, Pierfrancesco Tassone, Marcello Tucci, Vittorio Donato, Silvia Carrara, Salvatore Paiella, Oreste Gentilini, Roberta Gunelli, Fabrizio Nicolis, Fiamma Buttitta, Maurizio Colecchia, Matteo Fassan, Umberto Malapelle, Antonio Marchetti, Caterina Marchiò, Aldo Scarpa, Mauro Truini, Giuseppe Zamboni, Massimo Gion, Chiara Trevisiol, Alessandro Gronchi, Romano Danesi, Vito Di Marco, Paola Carrera, Paola Ghiorzo, Barbara Pasini, Liliana Varesco, Walter Artibani, Giuseppe Ludovico, Ornella Campanella, Simona Vatrano, Enrico Tagliafico
ESMO Open, 2022 - Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement
Giuseppe Badalamenti, Lorena Incorvaia, Laura Algeri, Annalisa Bonasera, Alessandra Dimino, Raimondo Scalia, Alessandra Cucinella, Giorgio Madonia, Federica Li Pomi, Antonio Galvano, Valerio Gristina, Francesca Toia, Adriana Cordova, Viviana Bazan, Antonio Russo
Therapeutic Advances in Medical Oncology, 2022 - Early detection screening: myth or reality?
M. La Mantia, F. Iacono, S. Cutaia, V. Gristina, A. Perez, M. Greco, K. Calcara, A. Galvano, V. Bazan, A. Russo
Liquid Biopsy New Challenges in the Era of Immunotherapy and Precision Oncology, 2022 - Future perspectives
L. Incorvaia, M. La Mantia, S. Cutaia, V. Gristina, A. Galvano, N. Barraco, A. Perez, G. Badalamenti, A. Russo, V. Bazan
Liquid Biopsy New Challenges in the Era of Immunotherapy and Precision Oncology, 2022 - Liquid biopsy: a right tool in a right context?
M. La Mantia, S. Cutaia, V. Gristina, A. Galvano, E. Capoluongo, C. Rolfo, U. Malapelle, L. Incorvaia, G. Badalamenti, A. Russo, V. Bazan
Liquid Biopsy New Challenges in the Era of Immunotherapy and Precision Oncology, 2022 - Liquid biopsy and immunotherapy: is all that glitter gold?
L. Incorvaia, A. Perez, C. Brando, V. Gristina, M. La Mantia, M. Castiglia, D. Fanale, A. Galvano, G. Badalamenti, A. Russo, V. Bazan
Liquid Biopsy New Challenges in the Era of Immunotherapy and Precision Oncology, 2022 - Current clinically validated applications of liquid biopsy
E. Capoluongo, C. Rolfo, A. Galvano, V. Gristina, A. Perez, N. Barraco, M. La Mantia, L. Incorvaia, G. Badalamenti, A. Russo, V. Bazan
Liquid Biopsy New Challenges in the Era of Immunotherapy and Precision Oncology, 2022 - Molecular tumor board
M. La Mantia, G. Busuito, V. Spinnato, V. Gristina, A. Galvano, S. Cutaia, N. Barraco, A. Perez, S. Cusenza, L. Incorvaia, G. Badalamenti, A. Russo, V. Bazan
Liquid Biopsy New Challenges in the Era of Immunotherapy and Precision Oncology, 2022 - Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study
Pasquale Pisapia, Francesco Pepe, Anna Baggi, Massimo Barberis, Antonio Galvano, Valerio Gristina, Fabrizio Mastrilli, Silvia Novello, Fabio Pagni, Silvia Pasini, Giuseppe Perrone, Daniela Righi, Antonio Russo, Giancarlo Troncone, Umberto Malapelle
Critical Reviews in Oncology Hematology, 2022 - The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
Antonio Galvano, Luisa Castellana, Valerio Gristina, Maria La Mantia, Lavinia Insalaco, Nadia Barraco, Alessandro Perez, Sofia Cutaia, Valentina Calò, Tancredi Didier Bazan Russo, Edoardo Francini, Lorena Incorvaia, Mario Giuseppe Mirisola, Salvatore Vieni, Christian Rolfo, Viviana Bazan, Antonio Russo
Therapeutic Advances in Medical Oncology, 2022 - A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic
Pasquale Pisapia, Francesco Pepe, Valerio Gristina, Maria La Mantia, Vincenzo Francomano, Gianluca Russo, Antonino Iaccarino, Antonio Galvano
Mediastinum, 2021 - Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
Francesco Passiglia, Antonio Galvano, Valerio Gristina, Nadia Barraco, Marta Castiglia, Alessandro Perez, Maria La Mantia, Antonio Russo, Viviana Bazan
Translational Lung Cancer Research, 2021 - The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
A. Galvano, V. Gristina, U. Malapelle, P. Pisapia, F. Pepe, N. Barraco, M. Castiglia, A. Perez, C. Rolfo, G. Troncone, A. Russo, V. Bazan
ESMO Open, 2021 - Tumor mutational burden on cytological samples: A pilot study
Francesco Pepe, Pasquale Pisapia, Valerio Gristina, Danilo Rocco, Mariacarolina Micheli, Pietro Micheli, Antonino Iaccarino, Rossella Tufano, Gianluca Gragnano, Gianluca Russo, Caterina De Luca, Roberta Sgariglia, Mariantonia Nacchio, Ilaria Girolami, Albino Eccher, Antonio Russo, Giancarlo Troncone, Umberto Malapelle
Cancer Cytopathology, 2021 - The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies
A. Russo, L. Incorvaia, M. Del Re, U. Malapelle, E. Capoluongo, V. Gristina, M. Castiglia, R. Danesi, M. Fassan, G. Giuffrè, S. Gori, A. Marchetti, N. Normanno, C. Pinto, G. Rossi, D. Santini, A. Sartore-Bianchi, N. Silvestris, P. Tagliaferri, G. Troncone, S. Cinieri, G.D. Beretta
ESMO Open, 2021 - Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
Valerio Gristina, Maria La Mantia, Antonio Galvano, Sofia Cutaia, Nadia Barraco, Marta Castiglia, Alessandro Perez, Marco Bono, Federica Iacono, Martina Greco, Katia Calcara, Valentina Calò, Sergio Rizzo, Lorena Incorvaia, Maria Chiara Lisanti, Giulia Santanelli, Delia Sardo, Sara Inguglia, Lavinia Insalaco, Luisa Castellana, Stefania Cusenza, Gianni Pantuso, Antonio Russo, Viviana Bazan
Journal of Molecular Pathology, 2021 - Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
Valerio Gristina, Antonio Galvano, Luisa Castellana, Lavinia Insalaco, Stefania Cusenza, Giuseppa Graceffa, Federica Iacono, Nadia Barraco, Marta Castiglia, Alessandro Perez, Sergio Rizzo, Antonio Russo, Viviana Bazan
Therapeutic Advances in Medical Oncology, 2021 - KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting
Mariantonia Nacchio, Roberta Sgariglia, Valerio Gristina, Pasquale Pisapia, Francesco Pepe, Caterina De Luca, Ilaria Migliatico, Eduardo Clery, Lorenza Greco, Elena Vigliar, Claudio Bellevicine, Antonio Russo, Giancarlo Troncone, Umberto Malapelle
Journal of Thoracic Disease, 2020 - The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Valerio Gristina, Umberto Malapelle, Antonio Galvano, Pasquale Pisapia, Francesco Pepe, Christian Rolfo, Silvia Tortorici, Viviana Bazan, Giancarlo Troncone, Antonio Russo
Cancer Treatment Reviews, 2020 - Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis
Antonio Galvano, Marta Castiglia, Sergio Rizzo, Nicola Silvestris, Oronzo Brunetti, Giovanni Vaccaro, Valerio Gristina, Nadia Barraco, Marco Bono, Giovanni Guercio, Giuseppa Graceffa, Fabio Fulfaro, Stefania Gori, Viviana Bazan, Antonio Russo
Cancers, 2020 - The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer
Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan
Pharmaceuticals, 2020 - Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
Antonio Galvano, Marta Peri, Aurelia Ada Guarini, Marta Castiglia, Antonino Grassadonia, Michele De Tursi, Luciana Irtelli, Sergio Rizzo, Alessandro Bertani, Valerio Gristina, Nadia Barraco, Antonio Russo, Clara Natoli, Viviana Bazan
Therapeutic Advances in Medical Oncology, 2020 - Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Nadia Barraco, Marco Bono, Lidia Rita Corsini, Antonio Galvano, Valerio Gristina, Angela Listì, Salvatore Vieni, Stefania Gori, Viviana Bazan, Antonio Russo
Advances in Therapy, 2019 - Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
Angela Listì, Nadia Barraco, Marco Bono, Lavinia Insalaco, Luisa Castellana, Sofia Cutaia, Maria Rita Ricciardi, Valerio Gristina, Enrico Bronte, Gianni Pantuso, Francesco Passiglia
Translational Cancer Research, 2019 - Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
Rossella De Luca, Livio Blasi, Massimiliano Alù, Valerio Gristina, Giuseppe Cicero
Drug Design Development and Therapy, 2018 - Diabetes and cancer: A critical appraisal of the pathogenetic and therapeutic links (review)
VALERIO GRISTINA, MARIA GRAZIA CUPRI, MARTINA TORCHIO, CLAUDIO MEZZOGORI, LAURA CACCIABUE, MARCO DANOVA
Biomedical Reports, 2015 - Circulating tumor cells: Current challenges and future perspectives
European Journal of Oncology, 2014 - Colorectal cancer with liver metastasis and treatment with anti-angiogenic drugs: Response evaluation with diffusion-weighted MRI
Iside Alessi, Federica Di Naro, Adriana Lena, Manuela Federico, Valerio Gristina
Euromediterranean Biomedical Journal, 2012
